Biopharmaceutical firm Cell Therapeutics Inc. (NASDAQ: CTIC) announced a secondary offering this morning of 60,000 shares of its Series 17 preferred stock at a price of $1,000.00 per share:
Each share of Series 17 Preferred Stock is convertible at the option of the holder, at any time, into approximately 714 shares of common stock at a conversion price of $1.40 per share of common stock, for a total of approximately 42.9 million shares of common stock.
The offering is being underwritten by Jefferies & Company Inc.
According to the announcement, the proceeds to Cell Therapeutics are expected to total $55.6 million and the company plans to use the funds to support the launch of its anticancer pixantrone drug in Europe and to begin phase III trials of another cancer drug, pacritinib.
Shareholders have driven the stock price into the ground this morning. Shares closed at $2.04 last night and are trading in the premarket this morning at $1.46, down 28%. The current 52-week range is $1.77 to $8.25.
Paul Ausick
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.